Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: Gilead Sciences is conducting a Phase 2/3 study titled A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants. The study aims to assess the safety and dosing of these drugs in children with HIV, which is crucial for improving pediatric HIV treatment options.
Intervention/Treatment: The study tests cobicistat-boosted Atazanavir (ATV/co), cobicistat-boosted Darunavir (DRV/co), and Emtricitabine/Tenofovir Alafenamide (F/TAF). These medications are intended to manage HIV in children by boosting the effectiveness of antiretroviral therapy.
Study Design: This is an interventional, non-randomized study with a parallel assignment model and no masking. The primary purpose is treatment, focusing on evaluating the safety and efficacy of the drugs in pediatric patients.
Study Timeline: The study began on January 16, 2014, and the last update was submitted on June 25, 2025. These dates are important as they indicate the study’s progress and the most recent data available.
Market Implications: This study update could positively impact Gilead Sciences’ stock performance by reinforcing its commitment to advancing HIV treatments, particularly in pediatric care. It also positions Gilead ahead of competitors in the pediatric HIV treatment market, potentially boosting investor confidence.
The study is ongoing, with further details available on the ClinicalTrials portal.